



Spotlight On: Tocilizumab

July 31, 2024

Technology: Tocilizumab is a humanized monoclonal antibody against the interleukin-6 (IL-6) receptor that inhibits IL-6 signaling and hinders IL-6's pro-inflammatory effects.







Spotlight On: Tocilizumab

VENABLE LLP

July 31, 2024

	Fresenius Kabi v. Chugai IPR2021-01024 Settled after institution	Fresenius Kabi v. Chugai IPR2021-01025 Settled after institution	Fresenius Kabi v. Chugai IPR2021-01288, IPR2021-01542 Settled after institution	Fresenius Kabi v. Chugai IPR2021-01336 Settled after institution	Fresenius Kabi v. Chugai IPR2022-00201 Settled after institution	Celltrion v. Chugai IPR2022-00578 Final Written Decision (All challenged claims unpatentable); Appeal 24-1115 voluntarily dismissed	Celltrion v. Chugai IPR2022-00579 Final Written Decision (All challenged claims unpatentable); Appeal 24-1111 voluntarily dismissed	Fresenius Kabi v. Chugai IPR2022- 01065 Settled before institution	Genentech v. Biogen 1:23-cv-11573 (D. Mass.) Settled
7,332,289									x
7,521,052	X								X
8,398,980									X
8,512,983									X
8,574,869									X
8,580,264			x			X			
8,734,800									x
9,714,293									x
9,750,752					x				
9,902,777									x
10,017,732									x
10,231,981								х	
10,336,983									x
10,501,769									x
10,662,237									x
10,676,710									X
10,744,201		X							X
10,829,732									X
10,874,677				X			X		
10,982,003									X
11,021,728									X
11,078,294									X
11,136,610									X
11,377,678									x